1. Home
  2. DHX vs ACRV Comparison

DHX vs ACRV Comparison

Compare DHX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DHI Group Inc.

DHX

DHI Group Inc.

HOLD

Current Price

$1.59

Market Cap

81.1M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.53

Market Cap

82.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHX
ACRV
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.1M
82.7M
IPO Year
2007
2022

Fundamental Metrics

Financial Performance
Metric
DHX
ACRV
Price
$1.59
$2.53
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$4.75
$14.67
AVG Volume (30 Days)
283.2K
531.6K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$131,236,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.21
$1.05
52 Week High
$3.34
$8.00

Technical Indicators

Market Signals
Indicator
DHX
ACRV
Relative Strength Index (RSI) 32.13 59.17
Support Level $1.69 $2.44
Resistance Level $1.92 $2.73
Average True Range (ATR) 0.08 0.17
MACD -0.01 0.01
Stochastic Oscillator 15.58 64.91

Price Performance

Historical Comparison
DHX
ACRV

About DHX DHI Group Inc.

DHI Group Inc is a provider of artificial intelligence-powered software products, online tools and services to deliver career marketplaces to candidates and employers globally. DHI's brands includes Dice and Clearance Jobs enable recruiters and hiring managers to efficiently search, match and connect with skilled technologists in specialized fields, particularly technology and those with active government security clearances. The company derive the majority of revenue came from the sale of recruitment packages, which allow customers to promote jobs on websites and source candidates through their resume databases. Recruitment packages are typically provided through contractual arrangements with annual, quarterly or monthly payment terms.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: